BEUDAMED
    FDA Adverse Event Injury Summary report: N

    BOND¿ READY-TO-USE PRIMARY ANTIBODY C-ERBB-2 ONCOPROTEIN

    MDR report key: 13385174 · Received January 28, 2022

    Report

    Report Number
    3004859032-2022-00002
    Event Type
    Injury
    Date Received
    January 28, 2022
    Date of Event
    November 24, 2021
    Report Date
    January 27, 2022
    Manufacturer
    LEICA BIOSYSTEMS NEWCASTLE LTD
    Product Code
    NJT
    UDI-DI
    05055331327901
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    US
    Reporter Occupation
    OTHER HEALTH CARE PROFESSIONAL
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    MANUFACTURER EVALUATION OF THE INFORMATION AVAILABLE, WHICH INCLUDES THE RELEVANT RUN EVENTS AND SERVICE EVENTS, INDICATES THAT THE TWO (2) SLIDES FOR WHICH FALSE POSITIVE STAINING WAS REPORTED (HEREAFTER REFERRED TO AS THE "AFFECTED SLIDES") WERE: - SLIDE ID 299E WITH CASE ID (B)(6) WHICH WAS STAINED AT SLIDE POSITION 5 ON SLIDE STAINING ASSEMBLY (SSA) 1 IN RUN 20651 EXECUTED ON (B)(6) 2021, AND - SLIDE ID 2BQ8 WITH CASE ID (B)(6) , WHICH WAS STAINED AT SLIDE POSITION 3 ON SSA 1 IN RUN 21164 EXECUTED ON 24 NOVEMBER 2021. STAINING OF BOTH AFFECTED SLIDES WAS PERFORMED USING BOND-III AUTOMATED STAINER SERIAL NUMBER (B)(6) COMPLETED SUCCESSFULLY WITH NO RECORDED EVENT(S) TO SUGGEST ANY MALFUNCTION(S) OF THE INSTRUMENT. ADDITIONALLY, SLIDE ID 299E WAS STAINED IN RUN 20651 TOGETHER WITH TWO (2) OTHER SLIDES WITH BOND SLIDE IDS 2994 AND 2997 USING THE SAME STAINING PROTOCOL AND THE SAME REAGENTS WITH NO PROBLEM REGARDING THE QUALITY OF STAINING REPORTED TO THE MANUFACTURER FOR SLIDES WITH SLIDE IDS 2994 AND 2997; AND SLIDE ID 2BQ8 WAS STAINED IN RUN 21164 TOGETHER WITH THREE (3) OTHER SLIDES WITH BOND SLIDE IDS 2BQB, 2BP8 AND 2BPQ USING THE SAME STAINING PROTOCOL AND THE SAME REAGENTS, WITH NO PROBLEM REGARDING THE QUALITY OF STAINING REPORTED TO THE MANUFACTURER FOR SLIDES WITH SLIDE IDS 2BQB, 2BP8 AND 2BPQ. THE INFORMATION AVAILABLE ALSO INDICATES THAT STAINING OF BOTH OF THE AFFECTED SLIDES WAS PERFORMED USING ON-THE-INSTRUMENT FACTORY DEFAULT *DEWAX PROTOCOL, WITH FACTORY DEFAULT HEAT INDUCED EPITOPE RETRIEVAL (HIER) PROTOCOL *HIER 40 MIN AND ER1/ AND CUSTOM STAINING PROTOCOL "HER2 JOES DAB" WITH LEICA BIOSYSTEMS BOND READY TO USE PRIMARY ANTIBODY *C-ERBB-2 ONCOPROTEIN (CLONE CB11) CATALOG NO: PA0571 AND THE BOND POLYMER REFINE DETECTION KIT. THE CLASS I, BOND READY-TO-USE PRIMARY ANTIBODY C-ERBB-2 ONCOPROTEIN (CB11) INSTRUCTIONS FOR USE CONTAIN THE FOLLOWING INFORMATION: "THE CLINICAL INTERPRETATION OF ANY STAINING OR ITS ABSENCE SHOULD BE COMPLEMENTED BY MORPHOLOGICAL STUDIES AND PROPER CONTROLS AND SHOULD BE EVALUATED WITHIN THE CONTEXT OF THE PATIENT'S CLINICAL HISTORY AND OTHER DIAGNOSTIC TESTS BY A QUALIFIED PATHOLOGIST.", AND "C-ERBB-2 ONCOPROTEIN (CB11) PRIMARY ANTIBODY WAS DEVELOPED FOR USE ON THE AUTOMATED BOND SYSTEM (INCLUDES LEICA BONDMAX SYSTEM AND LEICA BOND-III SYSTEM) IN COMBINATION WITH BOND POLYMER REFINE DETECTION. THE RECOMMENDED STAINING PROTOCOL FOR C-ERBB-2 ONCOPROTEIN (CB11) PRIMARY ANTIBODY IS IHC PROTOCOL F. HEAT INDUCED EPITOPE RETRIEVAL IS RECOMMENDED USING BOND EPITOPE RETRIEVAL SOLUTION 2 FOR 20 MINUTES." THE FACTS INDICATE THAT THE BOND READY-TO-USE PRIMARY ANTIBODY C-ERBB-2 ONCOPROTEIN (CB11) WAS NOT USED IN ACCORDANCE WITH THE MANUFACTURER RECOMMENDATIONS DETAILED IN THE INSTRUCTIONS FOR USE (IFU), BECAUSE THE AVAILABLE INFORMATION INDICATES THAT THE AFFECTED SLIDES WERE STAINED USING BOND EPITOPE RETRIEVAL SOLUTION 1 FOR 40 MINUTES RATHER THAN THE RECOMMENDED BOND EPITOPE RETRIEVAL SOLUTION 2 FOR 20 MINUTES; AND THE CUSTOM "HER2 JOES DAB" PROTOCOL USED FOR STAINING OF THE AFFECTED SLIDES IS NOT IDENTICAL TO THE RECOMMENDED IHC PROTOCOL F. LEICA BIOSYSTEMS NEWCASTLE CANNOT ASSESS THE IMPACT THIS MAY OR MAY NOT HAVE HAD ON THE QUALITY OF STAINING OF THE AFFECTED SLIDES. THE INFORMATION AVAILABLE SUGGESTS THAT RUN 20651 AND RUN 21164 HAD BOTH POSITIVE AND NEGATIVE TISSUE CONTROLS RUN. HOWEVER, INFORMATION AVAILABLE DOES NOT INDICATE THE TYPE OF CONTROL TISSUE USED AND WHETHER THEY WERE PLACED ON THE SAME SLIDES AS THE TISSUE FOR CASE ID (B)(6) AND CASE ID (B)(6) IN LINE WITH THE INSTRUMENT MANUFACTURER RECOMMENDATIONS IN SECTION 6.2 OF THE LEICA BIOSYSTEMS BOND SYSTEM USER MANUAL FOR BOND SYSTEMS RUNNING BOND 6.0 SOFTWARE (FOR USE ONLY IN THE USA) ENTITLED "WORKING WITH CONTROLS". THE RUN EVENTS FOR RUN 20651AND RUN 21164 DO NOT SUGGEST THAT SLIDES WITH CONTROL TISSUE WERE PLACED ON THE SAME SSA AS BOND SLIDE ID 299E WITH CASE ID (B)(6) AND BOND SLIDE ID 2BQ8 FOR CASE ID (B)(6) MANUFACTURER EVALUATION OF THE INFORMATION AVAILABLE DID NOT IDENTIFY ANY INSTRUMENT-OR REAGENT RELATED ROOT CAUSE FOR THE REPORTED FALSE POSITIVE STAINING OF BOND SLIDE ID 299E WITH CASE ID (B)(6) AND BOND SLIDE ID 2BQ8 FOR CASE ID (B)(6) FOLLOWING PROCESSING USING BOND-III AUTOMATED STAINER SERIAL NUMBER (B)(4). THE ROOT CAUSE OF THE FALSE POSITIVE STAINING REPORTED BY THE COMPLAINANT ON (B)(6) 2021 COULD NOT BE DETERMINED FROM THE INFORMATION AVAILABLE.

    Description of Event or Problem · 0

    ON (B)(6) 2021 AT 1:39PM EASTERN I RECEIVED AN EMAIL FROM (B)(6), LAB SUPERVISOR STATING THAT THEY HAD A PATIENT THAT WAS MISDIAGNOSED ON (B)(6) 2021 ACCORDING TO A POSITIVE HER-2 RESULT. THE PATIENT RECEIVED CHEMOTHERAPY BASED ON THE POSITIVE RESULT. ON (B)(6) 2021 THERE WAS A 2ND PATIENT WITH QUESTIONABLE RESULTS. THE CLINICIAN ASKED FOR A REPEAT OF THE 2ND PATIENT SPECIMEN WHICH TURNED OUT TO BE NEGATIVE. THE NEGATIVE RESULT FROM THE 2ND PATIENT PROMPTED THE LAB TO RE-TEST THE 1ST PATIENT FROM (B)(6). THE REPEAT SPECIMEN FROM (B)(6) WAS NEGATIVE. THE CLINICIAN WAS NOTIFIED OF THE CORRECTED RESULT. THE CLINICIAN INFORMED THE LAB THE PATIENT HAD ALREADY STARTED CHEMOTHERAPY. THUS BRINGING US TO CURRENT STATUS. REFER TO REPORT MRF 3004859032 2022 0001 FOR DETAILS OF PATIENT INVOLVED.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    1685107 BOND¿ READY-TO-USE PRIMARY ANTIBODY C-ERBB-2 ONCOPROTEIN BOND¿ READY-TO-USE PRIMARY ANTIBODY C-ERBB-2 ONCOPROTEIN - PA0571 NJT LEICA BIOSYSTEMS NEWCASTLE LTD PA0571 70113 05055331327901

    Patients

    Seq Age Sex Outcome Treatment
    1 68 YR Female Other